Cephalosporin drugs are bactericidal beta lactam antibiotics. These prevent the growth of bacteria by inhibiting cell wall synthesis, which effective in both type of bacteria i.e., gram-positive and gram-negative. The global cephalosporin market size was valued at $11,869 million in 2019, and is estimated to reach $14,022 million by 2028, growing at a CAGR of 3.0% from 2019 to 2028. Increase in incidence of population suffering from pneumonia, tonsillitis, bronchitis, and gonorrhea drives the market growth. In addition, increase in R&D activities to develop highly efficient & safe drugs, upsurge in use of combination therapies boost the growth of the market, and rise in incidence of pneumonia, tonsillitis, bronchitis, & gonorrhea. Hence, these aforementioned factors help in increasing the global cephalosporin market share.

Top Driver: Growing demand for ready to eat food will drive the market growth

The global cephalosporin drugs market is predicted to grow substantially thanks to increasing demand for anti-microbial in various indications, rising research and development activities, growing awareness among patients, increasing prevalence of infectious diseases, and special regulatory designation for pipeline molecule. Every year, November 18 is celebrated as the European Antibiotic Awareness Day, which helps to increase awareness about antibiotic resistance and promotes judicious use of antibiotics. Such programs about the disease and treatment options increase the treatment-seeking population, thereby boosting the expansion of the market. Additionally, low investment in R&D, stringent government policies, and generic saturation of these drugs fuel the growth of the market. Moreover, increasing mergers and acquisitions, use of combination therapies for treatment, and development of safe and highly efficient cephalosporin drugs are other factors likely to contribute to the growth of the market. However, weak pipeline molecules, development of drug resistance and resistance by governments on drug development are some challenges in the global cephalosporin drugs market.

First generation cephalosporin to Make Crucial Contribution for Growth of Global Cephalosporin drugs Market

The cephalosporin drugs market has been segmented supported spectrum of antimicrobial activity and route of administration. In terms of spectrum of antimicrobial activity, the market has been segmented into first generation, second generation, third generation, fourth generation, and fifth generation. First generation cephalosporin generates higher revenue than others due to its effectiveness against gram-positive bacteria such as streptococci and staphylococci. These also have gram-negative spectrum antimicrobial activity. Based on route of administration, the market has been segmented into injection and oral. Injection is that the most preferred route of drug administration thanks to quick drug delivery

   Asia-Pacific is predicted to be the Fastest Growing Segment within the Global Cephalosporin drugs Market

Asia-Pacific is predicted to dominate this market, thanks to the high prevalence of infectious diseases, increasing healthcare expenditure, and an outsized population base. Furthermore, the demand for better healthcare infrastructure and government initiatives is expected to help the growth of the market in this region. As per the statistics published by the World Health Organization (WHO) TB statistics for India for 2016, an estimated incidence of tuberculosis (TB) is 2.79 million cases in India. Thus, rising cases of varied infections are expected to spice up the general growth of the market. Asia-Pacific is followed by Europe, due to its large base of geriatric population and rising prevalence of infectious diseases in several countries of the region.

Players to Focus on Cephalosporin drugs Market

The cephalosporin drugs market is fragmented in terms of competition, owing to the presence of many small and large companies.  Some of the well-known players within the market studied include

• Astellas Pharma Inc.
• Baxter International, F.
• Hoffmann-La Roche AG
• GlaxoSmithKline PLC
• Lupin Pharmaceuticals
• Macleods Pharmaceuticals Ltd.
• Mankind Pharma
• Merck & Co. Inc.
• Pfizer Inc.
• Teva Pharmaceuticals.

Scope of the Report

By Generation

• First-Generation Cephalosporin
• Second-Generation Cephalosporin
• Third-Generation Cephalosporin
• Fourth-Generation Cephalosporin
• Fifth-Generation Cephalosporin

By Application

• Respiratory Tract Infection
• Skin Infection
• Ear Infection
• Sexually Transmitted Infection

By Route of Administration

• Injections
• Oral Drugs

By Region

• North America
• Europe
• Asia Pacific
• SAMEA

Key Reasons to Purchase this Report 

1. It provides a technological development map over time to understand the growth rate of the industry.

2. The report offers a dynamic method to various factors that drive or restrain the growth of the market.

3. It renders definite analysis for changing competitive dynamics.

4. It builds a seven-year estimate based on how the market is predicted to grow.